Taking imatinib after gastric mesenchymal tumor removal can prolong survival, and the treatment effect varies from person to person. Gastrointestinal mesenchymal tumor belongs to malignant tumors, patients often show abdominal pain, abdominal mass, gastrointestinal bleeding and other symptoms. Imatinib is an anticancer drug, belonging to tyrosine kinase inhibitors, clinically mainly used for the treatment of chronic granulocytic leukemia in the acute stage, accelerated stage or α-interferon treatment failure of the chronic stage of patients; can not be surgically resected or metastasis of malignant gastrointestinal mesenchymal tumor patients. In addition, nausea, vomiting, diarrhea and other adverse reactions may occur during the use of the drug. It is recommended to standardize the application under the guidance of professional doctors.